DOCSLIB.ORG

Learning Objectives

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2/26/2019 To help ensure the integrity of competition for Dirty Dozen: High Risk athletes, sports organizations and fans Sport Supplement worldwide. Ingredients Lara Gray, MS, RD, CSSD Senior Director of Education, Board Certified Sports Dietitian 1 Welcome! Learning Objectives Things to note: At the end of the presentation, attendees will 1. It is required by the BOC for Certified Athletic Trainers that you are actively be better able to: present in the live event AND complete the post-webinar survey in order to • Identify dietary ingredients that pose a threat to drug tested athletes. receive your CEU certificate. • Explain how high risk dietary ingredients are being used in sports 2. CEU Statements of Credit (if applicable) supplements. will be emailed to attendees no later than Friday, March 1st. • Analyze sports supplements for high risk dietary ingredients. 3. Please use the “Questions” box in GoToWebinar. Questions will be reviewed by the moderator and answered at the Drug Free Sport International (BOC AP# P8729) is approved by the Board of Certification, Inc. to end. provide continuing education to Athletic Trainers. This program is eligible for a maximum of 1 Category A hour/CEU. ATs should claim only those hours actually spent in the educational program. 4. Download today’s handouts from the “Handouts” tab. 1 2/26/2019 Today: An In-Depth Look 40% - 100% ATHLETES USE SUPPLEMENTS • Type of sport • Level of competition • Definition of supplements Garthe, Ina, and Ronald J. Maughan. "Athletes and Supplements: Prevalence and Perspectives." International journal of sport nutrition and exercise metabolism 28.2 (2018): 126‐138. The Dirty Dozen in 2019 1. Phenethylamine (PEA) Largest category of current “designer” drugs Stimulants Beta-phenethylamine ß-phenylethylamine 1. Phenethylamines (PEAs) N-phenethylamine 2. 2-aminoisoheptane 2-phenylethaneamine 3. AMPiberry Beta-methyl phenethylamine (BMPEA), 4. Advantra Z, Citrus aurantium, bitter orange Acacia rigidula 4-Fluoroethamphetamine 5. Nelumbo Nucifera (Lotus leaf), higenamine 6. IGF-1 Contributors: Colostrum, Deer antler velvet Often seen in products 7. Yohimbe, Yohimbine advertised for: 8. Noopept Pre-workout 9. Ostarine Energy 10. Cannabidiol Focus 11. Clomiphene “Lifestyle” products 12. Green tea extract Thermogenic/ Fat-burner Weight loss 2 2/26/2019 Phenethylamine (PEA) Phenethylamine (PEA) Endogenous and exogenous • Increases: – Heart rate Naturally occurring or synthetic Popular alkaloids in supplements - n-phenethyl dimethylamine – Respiration Similar to amphetamine – Blood pressure (Eria jarensis (orchid) extract) – Body temperature Similar side effects Hordenine N-methyl tyramine • Similar structure to dopamine – Effects on the brain • Can cause: – Hallucinations – Confusion CNS stimulants or hallucinogens – Depression – Dizziness Mescaline (peyote) – Nausea/vomiting Designer psychadelics – Diarrhea (Ecstasy/MDMA, 2C-B) – Headaches Dopamine – Body pains 2. 2-aminoisoheptane 2-aminoisoheptane Aconiti kusnezoffii, Aconite extract • Psychoactive CNS stimulant Juglans regia (Walnut bark) • Similar structure to DMAA, DMHA, dimethylhexylamine, AMP Citrate (DMBA), and Octodrine, 2-amino-6-methylheptane Ephedrine (synthetic), 2-metil-5-amino-eptano • Safety not established Studied as a drug in 1950s Reemerged in 2012, peaking in 2018 • Not a legal dietary ingredient Advertised as “legal” or “safe” alternative to other illegal stimulants 3 2/26/2019 • 2016 Trademark owned by LeCheek Nutrition, Inc – 2015: LeCheek receives warning letter from FDA • AMPilean and AMPItropin for listing AMP citrate 2-aminoisoheptane – LeCheek owns Insane Labz 3. AMPiberry Often seen in products • Claims related to “The New DMHA” advertised for: Juniperus communis – Stimulant effects Pre-workout (Juniper berry) – “Smooth energy curve” with caffeine Thermogenic/ Fat-burner • Other Claims Weight loss – Diuretic (most evidence, but rodent models) Seems oddly similar to AMP – Fat loss Reported side effects: citrate (4-amino-2- • Mood swings methylpentane citrate) or 1, • Tremors 3-dimethylbutylamine (DMBA) • Difficulty concentrating • Over-stimulation • Energy crashes Used in: • Anxiety Pre-workouts • High blood pressure • Difficulty breathing Energy • Tachycardia • Heartburn 5. Nelumbo Nucifera (Lotus leaf), Aconite, 4. Advantra Z Higenamine (typically synthetic), Norcoclaurine, Citrus aurantium demethylcoclaurine Bitter orange Beta-2 Agonist activity, Stimulant effects (cardiac) Contains: -tachycardia • Synephrine Found in: • But also: tyramine, n- • Pre-workout methyltyramine, • Energy hordenine and • Weight loss octopamine • Sleep (!) Doses tested in humans: Patented for: 2.5 – 5 mg Stimulating thermogenesis Reducing weight Increasing lean muscle mass Doses found in Improving athletic performance supplements: Suppressing appetite 0 - 60+ mg 4 2/26/2019 6. IGF-1 Contributors: 6. IGF-1 Contributors: Colostrum, Deer antler velvet Colostrum, Deer antler velvet IGF-1 = Insulin-like growth factor IGF-1 = Insulin-like growth factor WADA Prohibited under Peptide WADA Prohibited under Peptide Hormones, Growth Factors and Hormones, Growth Factors and Related Substances Related Substances PED potential: PED potential: Amplifies anabolic effects of Amplifies anabolic effects of human growth hormone human growth hormone Side effects: Side effects: Hypoglycemia, acromegaly, heart Hypoglycemia, acromegaly, heart palpatations, tumor growth palpatations, tumor growth Typically Found in: Typically Found in: Recovery, Joint Health Recovery, Joint Health Male Health Male Health Anabolic, Libido Anabolic, Libido Overall Well-being Overall Well-being 7. Yohimbe 7. Yohimbe Yohimbine (a Rx drug), Pausinystalia Serious side effects (dose Yohimbe (from bark of tree in Africa) dependent): Promoted for: aphrodisiac, erectile dysfunction, athletic performance (stimulant effects), weight loss • Cardiac arrhythmia • Heart attack • Kidney failure • Seizure • Nausea/vomiting, diarrhea • Decreased libido • Muscle aches • Tremors • Dizziness, headache, vertigo • Insomnia • Anxiety Significant stimulant activity – especially in association with other stimulants (i.e. caffeine) Dosage in supplements: Unlisted Found in: EVERYTHING with caffeine! (seemingly) Inaccurate (25-150% of listed amount) Thermogenic/Fat burner Pre-workout Weight loss Not specifically banned in Testosterone-booster sport. 5 2/26/2019 8. Noopept 9. Ostarine N-phenylacetyl-L-prolylglycine ethyl Enobosarm, MK-2866, GTx-024 ester, noopeptide, Ноопепт or GVS- 111 (Russian patent) Selective Androgen Receptor Modulator • A synthetic, more potent (SARM) analogue of Piracetam (a nootropic) • Research drug - NOT approved dietary ingredients • Nootropics: Promoted for neuro- • Similar to anabolic agents, but tissue cognitive enhancement specificity Not controlled substances Not FDA-approved drugs • NOT approved for human use Not approved as a dietary Amounts found in supplements 7-10 times higher than ingredient researched in clinical trials Long term risks unknown Effects: • Use is intentional (online purchase) or Mild cognitive boost (only unintentional (supplement contamination) evidenced in those with cognitive trauma) 410% increase in SARM-positive drug tests (2014-15 to Psychostimulant 2017-18) • Banned by ALL sport organizations Found in: Remain in the body 30+ days after use Brain/Memory enhancers Pre-workouts Solo/bulk products 10. CBD 10. CBD Cannabidiol Cannabidiol • Research drug (i.e. Epidiolex) NOT a Hemp Seed Oil vs dietary ingredient CBD Oil • Schedule I Controlled Substance •Cannabis seeds do not contain CBD or THC • No quality control Hemp seed • Not 100% “THC-free” • May contain other contaminants (pesticides, fungicides) Hemp oil (from seeds) • Clinical evidence for therapeutic uses in humans is ABSENT •Caution: “Hemp Oil” may be used • High risk for all sport organizations synonymously with CBD Oil • Specifically banned in MLB • Not TSA approved Hemp Extract = CBD, other cannabinoids 6 2/26/2019 Clomiphene-positive drug tests for 2018-19 are already 82% of last 11. Clomiphene year’s totals (with 6 months of testing 12. Green Tea Extract left) Selective Estrogen Receptor Camellia sinensis Modulator (SERM) Found in: • EVERYTHING (seemingly) FDA-approved drug for • Weight loss fertility treatment • MVI Products • Pre-workout/Energy • Not FDA-approved for men • Anabolics • Protein Blends Alters testosterone levels in • Brain-boosting men via negative feedback Health risks: • Small dose = anti-estrogen • Dizziness • Large dose = estrogen effect • Ringing in ears “We can send parcels all over the States.” • Decreased iron absorption Used to counter negative side effects • Increased BP and HR of anabolic steroids (i.e. gynomastia) • Liver damage 12. Green Tea Extract Camellia sinensis QUESTIONS? [email protected] Popular for: • Caffeine content • Polyphenol content Primary polyphenols: green tea catechins antioxidant, anti- inflammatory, anti- carcinogenic properties - Epicatechin - Epicatechin gallate - Epigallocatechin - Epigallocatechin gallate (most potent) 7 2/26/2019 Upcoming Webinars, 12-1pm CST Infographics 3/12 Recovery Nutrition Tips Speaker: Katie Knappenberger, MS, RD, CSSD, ATC, Director of Performance Nutrition at Northwestern Athletics 3/27 Addiction and the Young Mind Speaker: Megan Fowler, LMSW, Clinical Team Leader at First Call KC Available Now: https://www.drugfreesport.com/infographic-products/ [email protected] 1. Phenethylamines (PEAs) 2. 2-aminoisoheptane QUESTIONS? 3. AMPiberry 4. Advantra Z 5. Higenamine 6. IGF-1 Contributors 7. Yohimbe 8. Noopept 9. Ostarine 10. Cannabidiol 11. Clomiphene 12. Green tea extract 8.
Recommended publications
  • Enrichment of Biologically Active Compounds from Selected Plants

    Enrichment of Biologically Active Compounds from Selected Plants

    TECHNISCHE UNIVERSITÄT MÜNCHEN Lehrstuhl für Chemisch-Technische Analyse und Chemische Lebensmitteltechnologie Enrichment of Biologically Active Compounds from Selected Plants Using Adsorptive Bubble Separation Leonor Thompson Vollständiger Abdruck der von der Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt der Technische Universität München zur Erlangung des akademischen Grades eines Doktors der Naturwissenschaften (Dr. rer. nat.) genehmigten Dissertation. Vorsitzender: Univ.-Prof. Dr. K. Sommer Prüfer der Dissertation: 1. Univ.-Prof. Dr. H. Parlar 2. Univ.-Prof. Dr. K.-H. Engel Die Dissertation wurde am 16.06.2004 bei der Technischen Universität München eingereicht und durch die Fakultät Wissenschaftszentrum Weihenstephan für Ernährung, Landnutzung und Umwelt am 22.09.2004 angenommen. Dedicated to the memory of my late father, for instilling in me the desire to learn and the praise for the good values of Life Acknowledgements The research work presented in this PhD thesis was realised at the Chair for Chemical and Technical Analysis and Chemical Food Technology of the Technical University of Munich, in Freising, Weihenstephan. I would like to express my gratitude to: Prof. Dr. Harun Parlar, the Head of the Chair and my supervisor, for providing me with an interesting topic for the thesis, for the freedom to implement my ideas and the availability of funds for the financing of three years of work. Dr. Mehmet Coelhan, the head of my working group, for providing that the required means for the pursuance of my work were met, for the practical hints, particularly in relation with the HPLC and GC-MS analysis, as well as the interesting discussions regarding chemistry. Ms.
  • Tyler's Herbs of Choice: the Therapeutic Use of Phytomedicinals Category

    Tyler's Herbs of Choice: the Therapeutic Use of Phytomedicinals Category

    Tyler’s Herbs of Choice The Therapeutic Use of Phytomedicinals Third Edition © 2009 by Taylor & Francis Group, LLC Tyler’s Herbs of Choice The Therapeutic Use of Phytomedicinals Third Edition Dennis V.C. Awang Boca Raton London New York CRC Press is an imprint of the Taylor & Francis Group, an informa business © 2009 by Taylor & Francis Group, LLC CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2009 by Taylor & Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-0-7890-2809-9 (Hardcover) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher can- not assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers.
  • INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION of NATURAL PRODUCT SCAFFOLDS for the DEVELOPMENT of OPIOID RECEPTOR LIGANDS by Katherine M

    INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS By Katherine M. Prevatt-Smith Submitted to the graduate degree program in Medicinal Chemistry and the Graduate Faculty of the University of Kansas in partial fulfillment of the requirements for the degree of Doctor of Philosophy. _________________________________ Chairperson: Dr. Thomas E. Prisinzano _________________________________ Dr. Brian S. J. Blagg _________________________________ Dr. Michael F. Rafferty _________________________________ Dr. Paul R. Hanson _________________________________ Dr. Susan M. Lunte Date Defended: July 18, 2012 The Dissertation Committee for Katherine M. Prevatt-Smith certifies that this is the approved version of the following dissertation: INVESTIGATION OF NATURAL PRODUCT SCAFFOLDS FOR THE DEVELOPMENT OF OPIOID RECEPTOR LIGANDS _________________________________ Chairperson: Dr. Thomas E. Prisinzano Date approved: July 18, 2012 ii ABSTRACT Kappa opioid (KOP) receptors have been suggested as an alternative target to the mu opioid (MOP) receptor for the treatment of pain because KOP activation is associated with fewer negative side-effects (respiratory depression, constipation, tolerance, and dependence). The KOP receptor has also been implicated in several abuse-related effects in the central nervous system (CNS). KOP ligands have been investigated as pharmacotherapies for drug abuse; KOP agonists have been shown to modulate dopamine concentrations in the CNS as well as attenuate the self-administration of cocaine in a variety of species, and KOP antagonists have potential in the treatment of relapse. One drawback of current opioid ligand investigation is that many compounds are based on the morphine scaffold and thus have similar properties, both positive and negative, to the parent molecule. Thus there is increasing need to discover new chemical scaffolds with opioid receptor activity.
  • Molecular Signatures of G-Protein-Coupled Receptors A

    Molecular Signatures of G-Protein-Coupled Receptors A

    REVIEW doi:10.1038/nature11896 Molecular signatures of G-protein-coupled receptors A. J. Venkatakrishnan1, Xavier Deupi2, Guillaume Lebon1,3,4,5, Christopher G. Tate1, Gebhard F. Schertler2,6 & M. Madan Babu1 G-protein-coupled receptors (GPCRs) are physiologically important membrane proteins that sense signalling molecules such as hormones and neurotransmitters, and are the targets of several prescribed drugs. Recent exciting developments are providing unprecedented insights into the structure and function of several medically important GPCRs. Here, through a systematic analysis of high-resolution GPCR structures, we uncover a conserved network of non-covalent contacts that defines the GPCR fold. Furthermore, our comparative analysis reveals characteristic features of ligand binding and conformational changes during receptor activation. A holistic understanding that integrates molecular and systems biology of GPCRs holds promise for new therapeutics and personalized medicine. ignal transduction is a fundamental biological process that is comprehensively, and in the process expand the current frontiers of required to maintain cellular homeostasis and to ensure coordi- GPCR biology. S nated cellular activity in all organisms. Membrane proteins at the In this analysis, we objectively compare known structures and reveal cell surface serve as the communication interface between the cell’s key similarities and differences among diverse GPCRs. We identify a external and internal environments. One of the largest and most diverse consensus structural scaffold of GPCRs that is constituted by a network membrane protein families is the GPCRs, which are encoded by more of non-covalent contacts between residues on the transmembrane (TM) than 800 genes in the human genome1. GPCRs function by detecting a helices.
  • 18 December 2020 – to Date)

    18 December 2020 – to Date)

    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
  • (19) United States (12) Patent Application Publication (10) Pub

    (19) United States (12) Patent Application Publication (10) Pub

    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
  • Are Supplements Supplemented? Evaluating the Composition of Complementary and Alternative Medicines Using Mass Spectrometry and Metabolomics

    Are Supplements Supplemented? Evaluating the Composition of Complementary and Alternative Medicines Using Mass Spectrometry and Metabolomics

    Are supplements supplemented? Evaluating the composition of complementary and alternative medicines using mass spectrometry and metabolomics By Elly Gwyn Crighton BForensics in Forensic Biology & Toxicology (First Class Honours) BSc in Molecular Biology & Biomedical Science This thesis is presented for the degree of Doctor of Philosophy Perth, Western Australia at Murdoch University 2020 Declaration I declare that: i. The thesis is my own account of my research, except where other sources are acknowledged. ii. The extent to which the work of others has been used is clearly stated in each chapter and certified by my supervisors. iii. The thesis contains as its main content, work that has not been previously submitted for a degree at any other university. i Abstract The complementary and alternative medicines (CAM) industry is worth over US$110 billion globally. Products are available to consumers with little medical advice; with many assuming that such products are ‘natural’ and therefore safe. However, with adulterated, contaminated and fraudulent products reported on overseas markets, consumers may be placing their health at risk. Previous studies into product content have reported undeclared plant materials, ingredient substitution, adulteration and contamination. However, no large-scale, independent audit of CAM has been undertaken to demonstrate these problems in Australia. This study aimed to investigate the content and quality of CAM products on the Australian market. 135 products were analysed using a combination of next-generation DNA sequencing and liquid chromatography-mass spectrometry. Nearly 50% of products tested had contamination issues, in terms of DNA, chemical composition or both. 5% of the samples contained undeclared pharmaceuticals.
  • Barbara Lorson

    Barbara Lorson

    COMPARISON OF NEONATAL OUTCOMES IN MATERNAL USERS AND NON-USERS OF HERBAL SUPPLEMENTS A Thesis Presented in Partial Fulfillment of the Requirements for the Degree Master of Science in the Graduate School of The Ohio State University By Holly A Larson, B.S. ***** The Ohio State University 2008 Master‟s Examination Committee: Dr. Maureen Geraghty, Advisor Approved by Annette Haban Bartz ______________________________ Dr. Christopher A. Taylor Advisor Graduate Program in Allied Medical Professions COMPARISON OF NEONATAL OUTCOMES IN MATERNAL USERS AND NON-USERS OF HERBAL SUPPLEMENTS By Holly A. Larson, M.S. The Ohio State University, 2008 Dr. Maureen Geraghty, Advisor This pilot study was a retrospective chart review. The purposes of this study were to describe the prevalence herbal supplement use, to identify characteristics linked to increased herbal supplement use and, to identify adverse outcomes linked to herbal supplement use. Rate of use in the study sample of 2136 charts was 1.1% and identified 17 supplements. The most common supplements identified were teas. Characteristics of the neonates and controls were analyzed as appropriate and revealed no statistical significance. Characteristics of the mothers also revealed no statistical difference. There was a statistically significant difference between herbal users and herbal non-users and the trimester prenatal care began. Neonatal outcomes were statistically different on two measures. Further study is needed to be able to make recommendations regarding safety and efficacy of herbal supplements as well as to be able to better understand motives for choosing to use them. ii Dedicated to the Mama and the Daddy Bears iii ACKNOWLEDGMENTS I would like to express my heartfelt gratitude to my advisor, Dr.
  • Auckland Uniservices Limited

    Auckland Uniservices Limited

    Auckland UniServices Limited Legally available, unclassified psychoactive substances and illegal drugs in New Zealand before and after the ban on BZP: a web‐ based survey of patterns of use FINAL REPORT OF FINDINGS June 2009 Janie Sheridan, PhD, BPharm, BA, FRPharmS, RegPharmNZ Rachael Butler, BA, PGDipPH Christine Y. Dong, BSc Hons, BCom Hons Joanne Barnes, PhD, BPharm, MRPharmS, RegPharmNZ, FLS The School of Pharmacy The University of Auckland New Zealand TABLE OF CONTENTS 1 Executive Summary ........................................................................................... 7 2 Introduction .................................................................................................... 11 2.1 Background .............................................................................................. 11 2.1.1 The legislative and regulatory background ................................ 11 2.1.2 The current study ........................................................................ 12 2.2 Study aims ................................................................................................ 12 2.3 Study methods ......................................................................................... 13 2.4 Ethics approval ......................................................................................... 13 2.5 Structure of this report ............................................................................ 13 3 Adverse effects associated with herbal substances used for recreational purposes: a literature review
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al

    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
  • Last Decade of Unconventional Methodologies for the Synthesis Of

    Last Decade of Unconventional Methodologies for the Synthesis Of

    Review molecules Last Decade of Unconventional Methodologies for theReview Synthesis of Substituted Benzofurans Last Decade of Unconventional Methodologies for the Lucia Chiummiento *, Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli Synthesis of Substituted Benzofurans Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); [email protected] (M.F.); [email protected] (P.L.) Lucia Chiummiento * , Rosarita D’Orsi, Maria Funicello and Paolo Lupattelli * Correspondence: [email protected] Department of Science, Via dell’Ateneo Lucano, 10, 85100 Potenza, Italy; [email protected] (R.D.); Academic Editor: Gianfranco Favi [email protected] (M.F.); [email protected] (P.L.) Received:* Correspondence: 22 April 2020; [email protected] Accepted: 13 May 2020; Published: 16 May 2020 Abstract:Academic This Editor: review Gianfranco describes Favi the progress of the last decade on the synthesis of substituted Received: 22 April 2020; Accepted: 13 May 2020; Published: 16 May 2020 benzofurans, which are useful scaffolds for the synthesis of numerous natural products and pharmaceuticals.Abstract: This In review particular, describes new the intramolecular progress of the and last decadeintermolecular on the synthesis C–C and/or of substituted C–O bond- formingbenzofurans, processes, which with aretransition-metal useful scaffolds catalysi for thes or synthesis metal-free of numerous are summarized. natural products(1) Introduction. and (2) Ringpharmaceuticals. generation via In particular, intramolecular new intramolecular cyclization. and (2.1) intermolecular C7a–O bond C–C formation: and/or C–O (route bond-forming a). (2.2) O– C2 bondprocesses, formation: with transition-metal (route b).
  • Catalog Stable Isotope Standards for Clinical Mass Spectrometry

    Catalog Stable Isotope Standards for Clinical Mass Spectrometry

    Cambridge Isotope Laboratories, Inc. isotope.com Stable Isotope Standards For Clinical Mass Spectrometry Euriso-Top, Parc des Algorithmes, route de l'orme, 91190 Saint Aubin | France tel: +33 1 69 41 97 98 fax: +33 1 69 41 93 52 +49 (0) 681 99 63 338 (Germany) www.eurisotop.com Ordering Information The CIL Customer Service Department is open from 8:00 a.m. to 5:00 p.m. Eastern Time. Orders may be placed by fax, email or via our website 24 hours a day. Phone: 1.800.322.1174 (North America) +1.978.749.8000 Fax: +1.978.749.2768 Email: [email protected] [email protected] (International) Website: isotope.com Images used are for illustrative purposes only and may not be representative of actual product(s). isotope.com | Stable Isotope Standards for Clinical Mass Spectrometry Welcome Cambridge Isotope Laboratories, Inc. (CIL) is the world leader in the production and distribution of stable isotope-labeled compounds, providing labeled compounds for fields spanning from basic analytical chemistry to modern diagnostics. Over the years, CIL has evolved in its breadth and capacity to both produce and characterize a diverse array of organic compounds to support the development of mass spectrometry (MS) methods. Our ever-expanding product offering has been driven by close customer collaborations and partnerships that we’ve had the privilege of being involved in. It is with great pride that we present CIL’s new “Stable Isotope Standards for Clinical Mass Spectrometry” catalog. This compilation consists of a list of clinically relevant products and a collection of varied content pieces.